Superworth

Nephros NEPH

Medical - Instruments & Supplies, Healthcare
$3.24
+2.21%
Market cap
$35.2M
PE
20.3×
Forward PE
n/m
not a meaningful number
Price to sales
1.7×
EV/EBIT
18.6×
Revenue, 12 months
$20.7M
+24% on a year ago
Net margin
8.4%
Free cash flow yield
n/m
not a meaningful number

Nephros trades at 20.3× trailing earnings. Revenue was $20.7M over the last twelve months, up 24% on a year earlier with a 8% net margin.

Charts

Financials

Income statement for NEPH, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$3.7M+55%$3.3M+27%$3.5M−5%$3.3M−8%$3.5M−6%$3.9M+19%$4.9M+39%$4.4M+36%$4.8M+35%$4.7M+22%$5.2M+7%$6M+36%
Cost of revenue$1.5M−6%$1.2M+18%$1.3M−16%$1.3M−9%$1.4M−12%$1.4M+13%$1.7M+29%$1.6M+21%$1.8M+35%$2M+41%$2.2M+29%$2M+23%
Gross profit$2.2M+188%$2M+34%$2.2M+4%$1.9M−8%$2.1M−2%$2.5M+23%$3.2M+44%$2.8M+46%$2.9M+36%$2.8M+12%$3M−5%$4M+44%
R&D$205K−19%$208K−42%$212K−11%$254K+15%$188K−8%$252K+21%$295K+39%$311K+22%$338K+80%$395K+57%$346K+17%$366K+18%
SG&A$2.1M+23%$2.4M+35%$2.1M+1%$1.9M−13%$1.7M−20%$1.9M−22%$2.3M+5%$2.2M+13%$2.2M+30%$2.3M+24%$2.5M+12%$2.4M+10%
−$203K−84%−$649K−6%−$200K−35%−$317K−27%$206K$317K$566K$248K$314K+52%$18K−94%$97K−83%$1.2M+389%
Interest expense$0$1K−67%$1K+0%$0$0$0n/a$1K$0$0n/a$1K+0%
Pre-tax incomen/an/an/a−$289K$183K$364Kn/a$246K$340K+86%$62K−83%n/a$1.2M+392%
n/an/an/an/an/an/an/a$9K$3K$0n/a$13K+44%
Net income−$182K−94%n/a−$169K−45%−$289K−33%$183K$349K$558K$237K$337K+84%$62K−82%$140K−75%$1.2M+405%
−$0.02−94%−$0.06−33%−$0.02−33%−$0.03−25%$0.02$0.03$0.05$0.02$0.03+50%$0.01−67%$0.01−80%$0.11+450%
10.5M+2%10.5M+1%10.5M+2%10.5M+2%10.6M+1%10.6M+1%10.6M+1%10.8M+3%11M+4%11.3M+7%11M+4%11.1M+3%

EPS, diluted: 16 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 13 periods, Q4 FY10 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY17 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Instruments & Supplies nearest Nephros' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
NEPHNephros$35.2M20.3×28.3×1.7×+24%8.4%
APTAlpha Pro Tech$56.3M13.5×14.8×0.9×+6%6.8%
KEQUKewaunee Scientific$96.7M12.1×13.6×0.3×+5%3.0%
PDEXPro DEX$184.5M15.9×16.5×2.3×+13%15.1%
UTMDUtah Medical Products$224.6M21.5×20.9×6.2×−7%29.0%
INFUInfuSystem$275.7M33.8×43.5×1.9×+2%6.0%
EMBCEmbecta$350.7M4.2×11.6×0.3×−8%8.6%
Peer median$204.5M14.7×15.7×1.4×+4%7.7%

More on Nephros

Each number over time

Where it ranks

Its groups

About

Industry
Medical - Instruments & Supplies
Sector
Healthcare

Valuation data, not investment advice. Prices as of .